SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-007283
Filing Date
2021-05-14
Accepted
2021-05-14 16:30:33
Documents
75
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q otlk-20210331x10q.htm 10-Q 1321456
2 EX-31.1 otlk-20210331ex311567774.htm EX-31.1 9548
3 EX-32.1 otlk-20210331ex32153b564.htm EX-32.1 6322
  Complete submission text file 0001558370-21-007283.txt   6915280

Data Files

Seq Description Document Type Size
4 EX-101.INS otlk-20210331.xml EX-101.INS 1587734
5 EX-101.SCH otlk-20210331.xsd EX-101.SCH 54797
6 EX-101.CAL otlk-20210331_cal.xml EX-101.CAL 54092
7 EX-101.DEF otlk-20210331_def.xml EX-101.DEF 233326
8 EX-101.LAB otlk-20210331_lab.xml EX-101.LAB 419464
9 EX-101.PRE otlk-20210331_pre.xml EX-101.PRE 400524
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 21925155
SIC: 2836 Biological Products, (No Diagnostic Substances)